SCHEMBL3096934

SCHEMBL3096934

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cc(Cl)ccc2N)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.42
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
F2 P00734 2/20 0.41
F10 P00742 1/20 0.41
FADS1 O60427 1/20 0.40
PPARA Q07869 1/20 0.39
GPR27 Q9NS67 4/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
TP53 P04637 1/20 0.37
AVPR2 P30518 1/20 0.37
KAT6A Q92794 1/20 0.37
GCK P35557 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092294 1.00 LARS1 (0.42) LARS1MAPTGAAKDM4EMEN1
SCHEMBL3093418 0.94 FLT1 (0.43) LARS1MAPTGAAKDM4EMEN1
SCHEMBL3097119 0.94 FLT1 (0.43) LARS1MAPTGAAKDM4EMEN1
SCHEMBL3086418 0.91 LARS1 (0.42) LARS1MAPTF2F10GPR27
SCHEMBL3093678 0.91 LARS1 (0.42) LARS1MAPTF2F10GPR27
SCHEMBL3096503 0.91 LARS1 (0.45) LARS1MAPTMEN1NPC1KMT2A
SCHEMBL3096098 0.91 LARS1 (0.45) LARS1MAPTMEN1NPC1KMT2A
SCHEMBL3088260 0.91 LARS1 (0.42) LARS1MAPTMEN1KMT2AF2
SCHEMBL3097539 0.91 LARS1 (0.42) LARS1MAPTMEN1KMT2AF2
SCHEMBL3093396 0.90 LARS1 (0.41) LARS1MAPTGAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885MAPT 2813/4885GAA 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.